AR080505A1 - Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores - Google Patents

Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores

Info

Publication number
AR080505A1
AR080505A1 ARP110100782A ARP110100782A AR080505A1 AR 080505 A1 AR080505 A1 AR 080505A1 AR P110100782 A ARP110100782 A AR P110100782A AR P110100782 A ARP110100782 A AR P110100782A AR 080505 A1 AR080505 A1 AR 080505A1
Authority
AR
Argentina
Prior art keywords
treatment
methods
lymphoma
piperidin
dihydro
Prior art date
Application number
ARP110100782A
Other languages
English (en)
Spanish (es)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR080505A1 publication Critical patent/AR080505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP110100782A 2010-03-12 2011-03-11 Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores AR080505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31367010P 2010-03-12 2010-03-12

Publications (1)

Publication Number Publication Date
AR080505A1 true AR080505A1 (es) 2012-04-11

Family

ID=43799739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100782A AR080505A1 (es) 2010-03-12 2011-03-11 Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores

Country Status (11)

Country Link
US (3) US20110223157A1 (enExample)
EP (1) EP2544687A1 (enExample)
JP (1) JP2013522236A (enExample)
KR (1) KR20130038838A (enExample)
CN (1) CN103068386A (enExample)
AR (1) AR080505A1 (enExample)
AU (1) AU2011224166B2 (enExample)
CA (1) CA2792872A1 (enExample)
MX (1) MX2012010367A (enExample)
TW (1) TWI509247B (enExample)
WO (1) WO2011112933A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2898102A4 (en) 2012-09-20 2016-05-18 Univ Emory CLASSIFIERS OF NF-KB-PFADAKTIVIERUNG AND DEVICES AND METHODS OF USE THEREOF
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2908954C (en) * 2013-04-17 2021-08-03 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
WO2014179661A1 (en) 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
BR112016012792A2 (pt) * 2013-12-06 2017-08-08 Celgene Corp Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
WO2017044793A1 (en) 2015-09-11 2017-03-16 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of cereblon
WO2017059108A1 (en) 2015-09-29 2017-04-06 Htg Molecular Diagnostics, Inc. Methods for subtyping diffuse b-cell lymphoma (dlbcl)
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP2019520419A (ja) * 2016-07-13 2019-07-18 武田薬品工業株式会社 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用
US20180238886A1 (en) * 2017-01-31 2018-08-23 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CA3114401A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
US12400737B2 (en) * 2018-10-10 2025-08-26 Celgene Corporation Methods of classifying diffuse large B-cell lymphoma
CN122180665A (zh) * 2023-12-05 2026-06-09 浙江普洛家园药业有限公司 一种(s)-来那度胺-5-位衍生物及其合成方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0456950A1 (en) * 1990-05-16 1991-11-21 CONTRAVES ITALIANA S.p.A. Actuator for restraint/release (R/R) devices, particularly for space applications
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8367633B2 (en) * 2007-08-06 2013-02-05 University Of Rochester Methods of treating B-cell cancers
US7893045B2 (en) * 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US20090148853A1 (en) * 2007-12-07 2009-06-11 Schafer Peter H Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma

Also Published As

Publication number Publication date
CA2792872A1 (en) 2011-09-15
US20150174114A1 (en) 2015-06-25
US20110223157A1 (en) 2011-09-15
KR20130038838A (ko) 2013-04-18
TW201135231A (en) 2011-10-16
AU2011224166B2 (en) 2014-08-21
EP2544687A1 (en) 2013-01-16
CN103068386A (zh) 2013-04-24
AU2011224166A1 (en) 2012-10-04
WO2011112933A1 (en) 2011-09-15
MX2012010367A (es) 2012-11-23
US20160008344A1 (en) 2016-01-14
JP2013522236A (ja) 2013-06-13
TWI509247B (zh) 2015-11-21

Similar Documents

Publication Publication Date Title
CO2017003528A2 (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
EP4497824A3 (en) Methods and materials for assessing loss of heterozygosity
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
EP2464753A4 (en) METHODS AND COMPOSITIONS FOR BIODETECTION
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
GB2519906A (en) Methods and systems for detecting biological components
EA201590488A1 (ru) Способы модификации клеток-хозяев
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
EP2379577A4 (en) COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING WITHOUT GENETIC MODIFICATION
EA201590747A1 (ru) Способы лечения с использованием аденовируса
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
WO2011028880A3 (en) Methods for enhancing genome stability and telomere elongation in embryonic stem cells
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata

Legal Events

Date Code Title Description
FB Suspension of granting procedure